Navigation Links
NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance
Date:3/31/2009

SALT LAKE CITY, March 31 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that NASDAQ has filed a third grace period extension with the SEC, giving the company until approximately September 27, 2009, to comply with NASDAQ's $1 per share minimum bid rule.

"We are pleased that NASDAQ has again extended the timeframe for compliance," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will allow us time to announce our year-end results, which are expected to show significant improvement over the prior year."

Dynatronics recently reported a profit for the quarter ended December 31, 2008, showing substantially improved results for that period. The company also announced it had retained Vici Capital to assist in seeking ways to improve revenues and minimize expenses. Partly as a result of that process, the company has taken steps to reduce annual expenses by approximately $1,000,000. Additional savings are expected to be achieved in subsequent months from this effort.

"In the quarter ending June 30, 2009, we plan to introduce a new, high-margin product to the physical medicine market," Cullimore added. "The combination of new products, reduced expenses and improved revenues is expected to lead to significantly improved operating results and generate sustainable earnings improvements for the company."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations for future events. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements in this press release include the statements concerning anticipated improvements for the quarter ending June 30, 2009, the anticipated impact of the introduction of a new product in the quarter ending June 30, 2009, the expectation that changes implemented with the assistance of Vici Capital will reduce operating expenses by approximately $1,000,000, the expectation that additional savings are expected to be achieved in the coming months, and the statement that these developments are expected to lead to significantly improved operating results and generate sustainable earnings improvements for the company. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
2. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
3. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
6. The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo
7. Pharmacyclics Receives Nasdaq Notification
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
9. Cell Therapeutics to Resume Trading on MTA and NASDAQ
10. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
11. EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA Training Center ... Education Center headquartered in Northern California, has announced the addition of a Public ... health training to public sector employees. , “The primary goal of the Public ...
(Date:12/5/2016)... Angeles (PRWEB) , ... December 05, 2016 , ... What: ... feed of the North Pole to our patients – using a video monitor and ... video. The hospital will transform the Auditorium into a Christmas Wonderland, which is where ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Avamere Family of ... Avamere Transitional Care of Puget Sound ; located at 630 S Pearl ... will provide patients recovering from illness or injury with intensive skilled nursing and ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can ... 6th, sparks a conversation about epilepsy, bearing down on the social stigma and ... be diagnosed with epilepsy within their lifetime. With such a large percentage of ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  BioAtla, ... the development of Conditionally Active Biologic (CAB) ... Beijing Sinobioway Group Company, Limited (Sinobioway) selected ... development.  The specific program candidates and the ... 2015, BioAtla and Sinobioway entered into a ...
(Date:12/5/2016)... 2016 United Kingdom Ophthalmic Diagnostic Equipment ... new report, "United Kingdom Ophthalmic Diagnostic Equipment Market ... the United Kingdom Ophthalmic Diagnostic Equipment market. The ... volume (in units) and average prices (USD) within ... Ultrasound Imaging Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, ...
(Date:12/5/2016)... INTRODUCTION Since the ... as a crucial class of pharmacological interventions responsible ... are also used for prophylactic purposes in patients ... patients undergoing chemotherapy). However, the inappropriate use of ... rapidly accelerated an evolutionary response of antibiotic drug ...
Breaking Medicine Technology: